This observation suggests the VISTA protein has a potential target for cancer therapy [13,29,30,31], being tested in a phase I trial to treat patients with solid tumors, by targeting VISTA and PD-L1/PD-L2 proteins (NCT02812875) [32]. This evidence concerns the gene VSIR and cancer.